Erik Marshall, MD
Cardiovascular Disease · Newark, DENPI 1144223850
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.0% of the total across 208 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,308 and has fallen 64.6% since, to $463 in 2025.
Across 208 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$919
- Johnson & Johnson$466
- Amgen$462
- Boehringer Ingelheim$413
- E.r. Squibb & Sons, L.L.C.$373
- Novartis$287
- plus $1K from 20 others
What the payments were for
- Travel & lodging$2987%
- Food & beverage$3,92993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 11 | $919 |
| Johnson & Johnson | 31 | $466 |
| Amgen | 24 | $462 |
| Boehringer Ingelheim | 24 | $413 |
| E.r. Squibb & Sons, L.L.C. | 29 | $373 |
| Novartis | 20 | $287 |
| AstraZeneca | 15 | $229 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $186 |
| Lexicon Pharmaceuticals, Inc. | 6 | $146 |
| Pfizer | 7 | $140 |
| Astellas Pharma US Inc | 5 | $111 |
| Medtronic | 1 | $85 |
| Bayer | 3 | $60 |
| Amarin Pharma, Inc. | 4 | $55 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $53 |
| Esperion Therapeutics, Inc. | 2 | $40 |
| Alnylam Pharmaceuticals Inc. | 2 | $34 |
| Scpharmaceuticals Inc. | 1 | $30 |
| Lantheus Medical Imaging, Inc. | 1 | $24 |
| Heartflow, Inc. | 1 | $20 |
| Janssen Scientific Affairs, LLC | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Altathera Pharmaceuticals LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Bridgebio Pharma, Inc. | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip$449
How this compares
$4,227 in reported general payments places this provider in the 60th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 355 | $483,052 |
| XareltoRivaroxaban | 130 | $190,022 |
| JardianceEmpagliflozin | 55 | $67,113 |
| EntrestoSacubitril/Valsartan | 67 | $66,744 |
| Repatha SureclickEvolocumab | 14 | $17,014 |
| Repatha PushtronexEvolocumab | 14 | $10,821 |
| Metoprolol Succinate | 542 | $9,004 |
| Atorvastatin Calcium | 599 | $8,691 |
| Rosuvastatin Calcium | 250 | $4,973 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $4,748 |
| Ezetimibe | 140 | $4,458 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 28 | $3,847 |
| Ranolazine ErRanolazine | 45 | $3,564 |
| Losartan Potassium | 271 | $3,339 |
| Bumetanide | 27 | $2,898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $140 | $483,052355 claims |
| Johnson & JohnsonXarelto | $466 | $190,022130 claims |
| Boehringer IngelheimJardiance | $413 | $67,11355 claims |
| NovartisEntresto | $287 | $66,74467 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Newark
- Edward GoldenbergNewark$52K
- Muhammad ShakirNewark$47K
- Anthony AlfieriNewark$45K
- Sean DikdanNewark$42K
- Kirk GarrattNewark$38K
- Anthony ClayNewark$37K
- Ashish ParikhNewark$26K
- William WeintraubNewark$24K
- Wen Chi TsaiNewark$20K
- Stephen MengNewark$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.